Quick Answer
BioNexus Gene Lab Corp reported Stockholders Equity of $8.32 million for fiscal year 2024.
BioNexus Gene Lab Corp Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $8.32M | -13.8% |
| 2023 | $9.66M | +44.9% |
| 2022 | $6.67M | -7.2% |
| 2021 | $7.18M | +7.8% |
| 2020 | $6.66M | +493.6% |
| 2019 | $1.12M | -26.3% |
| 2018 | $1.52M | +1508.4% |
| 2017 | $94.6K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.82M | -27.4% | -9.4% |
| June 30, 2025 | $7.52M | -21.2% | -3.2% |
| March 31, 2025 | $7.77M | -16.8% | -6.6% |
| December 31, 2024 | $8.32M | -13.8% | -11.3% |
| September 30, 2024 | $9.39M | +0.8% | -1.7% |
| June 30, 2024 | $9.55M | +70.7% | +2.2% |
| March 31, 2024 | $9.34M | +51.1% | -3.2% |
| December 31, 2023 | $9.66M | +44.9% | +3.7% |
- BioNexus Gene Lab Corp showed a decrease of -13.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2024 period, BioNexus Gene Lab Corp’s stockholders equity has grown by 8695.5% (from $94.6 thousand to $8.32 million).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: